ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
Samus Therapeutics Launches PU-AD Clinical Program in Alzheimer's Disease americanpharmaceuticalreview
July 25, 2019Samus Therapeutics announced the initiation of its clinical program for PU-AD, an oral, brain permeable inhibitor of epichaperomes in Alzheimer's Disease (AD) following clearance of its Investigational New Drug (IND) application by the U.S. Food and Drug -
Samus Therapeutics Launches PU-AD Clinical Program in Alzheimer's Disease americanpharmaceuticalreview
July 24, 2019Samus Therapeutics announced the initiation of its clinical program for PU-AD, an oral, brain permeable inhibitor of epichaperomes in Alzheimer's Disease (AD) following clearance of its Investigational New Drug (IND) application by the U.S. Food and Drug
Pharma Sources Insight January 2025
